These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29599970)

  • 1. Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?
    Knoeff J; Flühmann B; Mühlebach S
    Eur J Hosp Pharm; 2018 Mar; 25(2):79-84. PubMed ID: 29599970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Iron-Carbohydrate Nanoparticles and Their Similars. What Do We Choose?
    Mehedinti AM; Capusa C; Andreiana I; Mircescu G
    Maedica (Bucur); 2022 Jun; 17(2):436-448. PubMed ID: 36032600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tackling the challenges of nanomedicines: are we ready?
    Hertig JB; Shah VP; Flühmann B; Mühlebach S; Stemer G; Surugue J; Moss R; Di Francesco T
    Am J Health Syst Pharm; 2021 Jun; 78(12):1047-1056. PubMed ID: 33599767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicines in clinical practice: Are colloidal iron sucrose ready-to-use intravenous solutions interchangeable?
    Di Francesco T; Sublet E; Borchard G
    Eur J Pharm Sci; 2019 Apr; 131():69-74. PubMed ID: 30742979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD.
    Praschberger M; Cornelius C; Schitegg M; Goldenberg H; Scheiber-Mojdehkar B; Sturm B
    Pharm Dev Technol; 2015 Mar; 20(2):176-82. PubMed ID: 24219061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Do Hospital Pharmacists Approach Substitution of Nanomedicines? Insights from a Qualitative Pilot Study and a Quantitative Market Research Analysis in Five European Countries.
    Sofia N; Mühlebach S; Musazzi UM; Khatib R; Martinez Sesmero JM; Lipp HP; Surugue J; Di Francesco T; Flühmann B
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator.
    Stein J; Dignass A; Chow KU
    Curr Med Res Opin; 2012 Feb; 28(2):241-3. PubMed ID: 22181342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to select a nanosimilar.
    Astier A; Barton Pai A; Bissig M; Crommelin DJA; Flühmann B; Hecq JD; Knoeff J; Lipp HP; Morell-Baladrón A; Mühlebach S
    Ann N Y Acad Sci; 2017 Nov; 1407(1):50-62. PubMed ID: 28715605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations.
    Klein K; Stolk P; De Bruin ML; Leufkens HGM; Crommelin DJA; De Vlieger JSB
    Eur J Pharm Sci; 2019 May; 133():228-235. PubMed ID: 30953753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
    Pai AB
    Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider.
    Schellekens H; Stegemann S; Weinstein V; de Vlieger JS; Flühmann B; Mühlebach S; Gaspar R; Shah VP; Crommelin DJ
    AAPS J; 2014 Jan; 16(1):15-21. PubMed ID: 24065600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron sucrose: assessing the similarity between the originator drug and its intended copies.
    Di Francesco T; Philipp E; Borchard G
    Ann N Y Acad Sci; 2017 Nov; 1407(1):63-74. PubMed ID: 29168243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision.
    Gaspar RS; Silva-Lima B; Magro F; Alcobia A; da Costa FL; Feio J
    Front Med (Lausanne); 2020; 7():590527. PubMed ID: 33330550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-minimization analysis between intravenous iron sucrose and iron sucrose similar in hemodialysis patients.
    Pagès A; Porteils C; Labadens I; Parmier M; Oses S; Semely D; Bourdoncle M; Seigneuric B; Del Bello A; Juillard-Condat B
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):281-287. PubMed ID: 31257944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic substitution practices in short-term hospitals.
    Doering PL; Klapp DL; McCormick WC; Russell WL
    Am J Hosp Pharm; 1982 Jun; 39(6):1028-32. PubMed ID: 7102686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model.
    Toblli JE; Cao G; Angerosa M
    J Clin Diagn Res; 2015 Dec; 9(12):FF08-12. PubMed ID: 26816915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.
    Macdougall IC; Comin-Colet J; Breymann C; Spahn DR; Koutroubakis IE
    Adv Ther; 2020 May; 37(5):1960-2002. PubMed ID: 32297281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
    Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
    J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
    Rottembourg J; Rostoker G
    Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.